Nucleai

Nucleai has developed an advanced AI-powered spatial biology platform that analyzes pathology slides to extract deep insights into the tumor microenvironment. Their technology enables precise mapping of cellular interactions within tissue samples—helping biopharma companies optimize biomarker discovery and validation, improve patient selection for clinical trials (especially in oncology), and accelerate the development of next-generation therapeutics such as ADCs and bispecific antibodies. Recent collaborations have identified novel metabolic signatures linked to immunotherapy resistance in lung cancer patients. The company’s solutions are used by leading biopharma firms in both translational research and prospective trial enrollment settings.